Patents by Inventor Yoshinori Kitagawa
Yoshinori Kitagawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240072203Abstract: A method for fabricating light emitting diode (LED) dice includes the steps of: providing a substrate, and forming a plurality of die sized semiconductor structures on the substrate. The method also includes the steps of providing a receiving plate having an elastomeric polymer layer, placing the substrate and the receiving plate in physical contact with an adhesive force applied by the elastomeric polymer layer, and performing a laser lift-off (LLO) process by directing a uniform laser beam through the substrate to the semiconductor layer at an interface with the substrate to lift off the semiconductor structures onto the elastomeric polymer layer. During the laser lift-off (LLO) process the elastomeric polymer layer functions as a shock absorber to reduce momentum transfer, and as an adhesive surface to hold the semiconductor structures in place on the receiving plate.Type: ApplicationFiled: November 6, 2023Publication date: February 29, 2024Applicants: SemiLEDs Corporation, SHIN-ETSU CHEMICAL CO., LTD.Inventors: Chen-Fu Chu, Shih-Kai Chan, Yi-Feng Shih, David Trung Doan, Trung Tri Doan, Yoshinori Ogawa, Kohei Otake, Kazunori Kondo, Keiji Ohori, Taichi Kitagawa, Nobuaki Matsumoto, Toshiyuki Ozai, Shuhei Ueda
-
Publication number: 20230348573Abstract: An antibody against spike protein of SARS-CoV-2 is provided, the antibody having a specific heavy chain variable region and a specific light chain variable region, or a fragment of the antibody, the antibody or fragment thereof inhibiting the binding between the spike protein of SARS-CoV-2 and ACE2, the antibody or fragment thereof inhibiting SARS-CoV-2 infection; and a pharmaceutical composition including the antibody or fragment thereof and a pharmaceutically acceptable carrier, the pharmaceutical composition including two or more kinds of the antibody or fragment thereof.Type: ApplicationFiled: September 24, 2021Publication date: November 2, 2023Applicants: KEIO UNIVERSITY, JAPAN as represented by DIRECTOR GENERAL of NATIONAL INSTITUTE OF INFECTIOUS DISEASES, RIKEN, SHIGA UNIVERSITY OF MEDICAL SCIENCE, THE UNIVERSITY OF TOKYOInventors: Masaru TAKESHITA, Tsutomu TAKEUCHI, Katsuya SUZUKI, Hideyuki SAYA, Yoshimasa TAKAHASHI, Saya MORIYAMA, Hidehiro FUKUYAMA, Chieko OKAMURA, Mikako SHIROUZU, Takehisa MATSUMOTO, Katsuhiko KAMADA, Yasushi ITOH, Hirohito ISHIGAKI, Misako NAKAYAMA, Yoshinori KITAGAWA, Yoshihiro KAWAOKA
-
Publication number: 20230279361Abstract: The present invention addresses the problem of providing a more convenient method for in vitro proliferating a virus belonging to the family Coronaviridae at high proliferation accuracy. This problem is solved by an in vitro virus proliferation method, said method comprising a step for culturing kidney-derived cells, which have been contacted with the virus belonging to the family Coronaviridae, with a use of a cell culture medium to which a protease having an optimum pH of from 7 to 9 is added.Type: ApplicationFiled: July 27, 2021Publication date: September 7, 2023Inventors: Yasushi ITOH, Hirohito ISHIGAKI, Misako NAKAYAMA, Yoshinori KITAGAWA
-
Patent number: 9598494Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: GrantFiled: October 17, 2014Date of Patent: March 21, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Matsushima
-
Patent number: 9023361Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: GrantFiled: April 4, 2014Date of Patent: May 5, 2015Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Matsushima
-
Patent number: 9023360Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: GrantFiled: September 4, 2013Date of Patent: May 5, 2015Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Matsushima
-
Publication number: 20150057437Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: ApplicationFiled: October 17, 2014Publication date: February 26, 2015Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: NOBUAKI TAKAHASHI, TORU MIURA, YOSHINORI KITAGAWA, AKI MATSUSHIMA
-
Publication number: 20140248266Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: ApplicationFiled: April 4, 2014Publication date: September 4, 2014Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Matsushima
-
Publication number: 20140105907Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: ApplicationFiled: September 4, 2013Publication date: April 17, 2014Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Matsushima
-
Patent number: 8568725Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: GrantFiled: December 24, 2004Date of Patent: October 29, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Hirano
-
Patent number: 7972809Abstract: This invention is to provide a process for producing a glycoprotein comprising a mammalian type sugar chain, characterized in that the process comprises introducing an ?-1,2-mannosidase gene into a methylotrophic yeast having a mutation of a sugar chain biosynthesizing enzyme gene, so that the ?-1,2-mannosidase gene is expressed under the control of a potent promoter in the yeast; culturing in a medium the methylotrophic yeast cells with a heterologous gene transferred thereinto; and obtaining the glycoprotein comprising a mammalian type sugar chain from the culture. Using the newly created methylotrophic yeast having a sugar chain mutation, a neutral sugar chain identical with a high mannose type sugar chain produced by mammalian cells such as human cells, or a glycoprotein comprising such a neutral sugar chain, can be produced in a large amount at a high purity.Type: GrantFiled: April 28, 2003Date of Patent: July 5, 2011Assignees: National Institute of Advanced Industrial Science & Technology, Kirin Beer Kabushiki KaishaInventors: Kazuo Kobayashi, Yoshinori Kitagawa, Toshihiro Komeda, Nagako Kawashima, Yoshifumi Jigami, Yasunori Chiba
-
Publication number: 20100249248Abstract: The present invention aims to provide ligand agents for peroxisome proliferator-activated receptors (PPARs), etc. The ligand agents of the present invention are characterized by comprising, as an active ingredient, an extract of one or more plants selected from the following: Serenoa repens, Acanthopanax senticosus, Euterpe oleracea, Elettaria cardamomum, Angelica archangelica, Psidium guajava, Prumus spinosa, Eleagnus multiflora, Ligusticum chuaxiong, Cannabis sativa, Sambucus nigra, Adinandra nitida, Passiflora incarnata, Peucedanum japonicum, Pimpinella anisum, Vitex agnus-castus, Withania somnifera, Calluna vulgaris, Crataegus monogyna, Linum usitatissimum, Pleurotus ferulae, Robinia pseudoacacia, and Acanthopanax sessiliflorus.Type: ApplicationFiled: October 24, 2008Publication date: September 30, 2010Applicant: Suntory Holdings LimitedInventors: Kyoichi Ogura, Mitsuru Maeda, Tomohiro Rogi, Yoshinori Kitagawa, Kahori Shimada
-
Patent number: 7696355Abstract: Novel isothiazolecarboxamides of the formula in which R is as defined in the description, a plurality of processes for preparing the novel compounds and their use for protecting plants against attack by undesirable microorganisms and animal pests.Type: GrantFiled: October 30, 2006Date of Patent: April 13, 2010Assignee: Bayer AktiengesellschaftInventors: Lutz Assmann, Dietmar Kuhnt, Hans-Ludwig Elbe, Christoph Erdelen, Stefan Dutzmann, Gerd Hänssler, Klaus Stenzel, Astrid Mauler-Machnik, Yoshinori Kitagawa, Haruko Sawada, Haruhiko Sakuma
-
Publication number: 20070232670Abstract: Novel isothiazolecarboxamides of the formula in which R is as defined in the description, a plurality of processes for preparing the novel compounds and their use for protecting plants against attack by undesirable microorganisms and animal pests.Type: ApplicationFiled: October 30, 2006Publication date: October 4, 2007Inventors: Lutz Assmann, Dietmar Kuhnt, Hans-Ludwig Elbe, Christoph Erdelen, Stefan Dutzmann, Gerd Hanssler, Klaus Stenzel, Astrid Mauler-Machnik, Yoshinori Kitagawa, Haruko Sawada, Haruhiko Sakuma
-
Publication number: 20070148163Abstract: A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the ADCC and/or CDC activities therein, and a mutant of an antagonistic anti-CD40 antibody, comprising at least one mutation or substitution in the constant region to reduce the ADCC and/or CDC activities therein, both mutants having at least a hinge region derived from a human IgG2.Type: ApplicationFiled: December 24, 2004Publication date: June 28, 2007Inventors: Nobuaki Takahashi, Toru Miura, Yoshinori Kitagawa, Aki Hirano
-
Patent number: 7189680Abstract: The invention relates to novel triazolopyrimidines of the formula in which R1, R2, R3 and X have the meanings given in the disclosure, and acid addition salts thereof, to a plurality of processes for preparing these novel substances, and to their use for controlling unwanted microorganisms. The invention further relates to novel amines and carbamates of the formulae indicated in the description and to processes for preparing these intermediates.Type: GrantFiled: April 16, 2002Date of Patent: March 13, 2007Assignee: Bayer Cropscience AGInventors: Olaf Gebauer, Jörg Nico Greul, Ulrich Heinemann, Hans-Ludwig Elbe, Bernd-Wieland Krüger, Ralf Dunkel, Arnd Voerste, Ronald Ebbert, Astrid Mauler-Machnik, Ulrike Wachendorff-Neumann, Karl-Heinz Kuck, Yoshinori Kitagawa
-
Patent number: 7186831Abstract: This invention relates to novel triazolopyrimidines of the formula in which R1, R2, R3, R4and X have the meanings given in the disclosure, to a plurality of processes for preparing these novel substances, and to their use for controlling unwanted microorganisms. This invention further relates to novel intermediates of the formulae and processes for their preparation and additionally relates to novel amines and carbamates of the formulae given in the disclosure and processes for their preparation.Type: GrantFiled: April 18, 2002Date of Patent: March 6, 2007Assignee: Bayer Cropscience LPInventors: Olaf Gebauer, Jörg Nico Greul, Ulrich Heinemann, Hans-Ludwig Elbe, Bernd-Wieland Krüger, Fritz Maurer, Ralf Dunkel, Arnd Voerste, Ronald Ebbert, Ulrike Wachendorff-Neumann, Yoshinori Kitagawa, Astrid Mauler-Machnik, Karl-Heinz Kuck
-
Patent number: 7157481Abstract: Novel isothiazolecarboxamides of the formula in which R is as defined in the description, a plurality of processes for preparing the novel compounds and their use for protecting plants against attack by undesirable microorganisms and animal pests.Type: GrantFiled: December 22, 2004Date of Patent: January 2, 2007Assignee: Bayer AktiengesellschaftInventors: Lutz Assmann, Dietmar Kuhnt, Hans-Ludwig Elbe, Christoph Erdelen, Stefan Dutzmann, Gerd Hänssler, Klaus Stenzel, Astrid Mauler-Machnik, Yoshinori Kitagawa, Haruko Sawada, Haruhiko Sakuma
-
Publication number: 20060148039Abstract: This invention is to provide a process for producing a glycoprotein comprising a mammalian type sugar chain, characterized in that the process comprises introducing an ?-1,2-mannosidase gene into a methylotrophic yeast having a mutation of a sugar chain biosynthesizing enzyme gene, so that the ?-1,2-mannosidase gene is expressed under the control of a potent promoter in the yeast; culturing in a medium the methylotrophic yeast cells with a heterologous gene transferred thereinto; and obtaining the glycoprotein comprising a mammalian type sugar chain from the culture. Using the newly created methylotrophic yeast having a sugar chain mutation, a neutral sugar chain identical with a high mannose type sugar chain produced by mammalian cells such as human cells, or a glycoprotein comprising such a neutral sugar chain, can be produced in a large amount at a high purity.Type: ApplicationFiled: April 28, 2003Publication date: July 6, 2006Inventors: Kazuo Kobayashi, Yoshinori Kitagawa, Toshihiro Komeda, Nagako Kawashima, Yoshifumi Jigami, Yasumori Chiba
-
Publication number: 20050159464Abstract: Novel isothiazolecarboxamides of the formula in which R is as defined in the description, a plurality of processes for preparing the novel compounds and their use for protecting plants against attack by undesirable microorganisms and animal pests.Type: ApplicationFiled: December 22, 2004Publication date: July 21, 2005Inventors: Lutz Assmann, Dietmar Kuhnt, Hans-Ludwig Elbe, Christoph Erdelen, Stefan Dutzmann, Gerd Hanssler, Klaus Stenzel, Astrid Mauler-Machnik, Yoshinori Kitagawa, Haruko Sawada, Haruhiko Sakuma